Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — Q3 2011 Earnings Presentation

15 slides from Questcor Pharmaceuticals's earnings presentation, Oct 27, 2011

  1. Slide 1: Third Quarter 2011 Conference Call

    1 NASDAQ: QCOR Third Quarter 2011 Conference Call Exhibit 99.3 NASDAQ: QCOR Third Quarter 2011 Conference Call

  2. Slide 2: Conference Call Logistics

    2 • • Telephone replay is available by dialing: – U.S.: 800-406-7325 – International: 303-590-3030 – Replay Passcode: 4480054 Conference Call Logistics • • Telephone replay is available by dialing: – U.S.: 800-406-7325 – International: 303-590-3030 – Replay Passcode: 4480054 Today’s webcast, accompa

  3. Slide 3: Safe Harbor Statement

    3 Safe Harbor Statement The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance. Note: Except for the historical information contained herein, this press release contains forward-looking statements t

  4. Slide 4: Strong Third Quarter Results

    4 • 886 paid MS scripts – Up 174% YOY – Up 18% sequentially • 60 paid NS scripts – Much better than expected – Sales force expansion complete • Record financial performance – 2,910 vials – $59.8M in net sales – $0.35 EPS Strong Third Quarter Results • 886 paid MS scripts – Up 174% YOY – Up 18% seque

  5. Slide 5: MS Sales - Record of Consistent Growth

    5 MS Sales - Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which i

  6. Slide 6: Monthly MS Sales Have 160% CAGR

    6 Monthly MS Sales Have 160% CAGR 15-30 reps 30-38 reps 38-77 reps

  7. Slide 7: NS Sales – Off to a Good Start

    7 NS Sales – Off to a Good Start New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the fo

  8. Slide 8: MS Sales - Record of Consistent Growth

    8 MS Sales - Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which i

  9. Slide 9: NS Sales – Off to a Good Start

    9 NS Sales – Off to a Good Start New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the fo

  10. Slide 10: Total Acthar Sales Force

    10 • Specialty Sales Force – Main focus on MS (~80%), 15% on NS, 5% on IS – 77 representatives, 13 regional managers, one national director • Nephrology Sales Force – Focus 100% on nephrotic syndrome – 28 representatives, 4 regional managers, one national director • Combined Forces are calling on –

  11. Slide 11: ASN Annual Meeting 2011: Acthar-Related Abstracts

    11 • Treatment of Resistant Glomerular Diseases with ACTH Gel: A Prospective Trial [G. Appel, et al ] • Response of Anti-PLA2R to Adrenocorticotropic hormone (ACTH) Gel in Primary Membranous Nephropathy [L. Beck, et al ] • Adrenocortocortropin (ACTH) gel suppresses renal tubulointerstitial inflammat

  12. Slide 12: Q3-2011 Financial Results

    12 Record Net Sales (up 91%) and Solid Earnings (EPS up 94%) Q3-2011 Q3-2010 12 Q3-2011 Financial Results Record Net Sales (up 91%) and Solid Earnings (EPS up 94%) • Third quarter vials shipped: 2,910 • Third quarter cash flow from operations: $32.6M • Channel inventory estimated to be within histor

  13. Slide 13: Debt-free balance sheet; Questcor is Cash Flow Positive

    13 10/21/11 Debt-free balance sheet Questcor is Cash Flow Positive *After return of $78 million of cash to shareholders through share repurchases. Cash / ST Investments Accounts Receivable $180M* $24M Debt-free balance sheet

  14. Slide 14: Investment Highlights

    14 Investment Highlights Acthar has sustainable competitive advantages-without FDA approval risk Acthar is approved for 19 indications-many in large markets with sizable unmet need Sales in MS and NS are growing rapidly, yet market penetration is low High margins provide good operating leverage Prof

  15. Slide 15: Third Quarter 2011 Conference Call

    15 NASDAQ: QCOR Third Quarter 2011 Conference Call NASDAQ: QCOR Third Quarter 2011 Conference Call

Questcor Pharmaceuticals — Q3 2011 Earnings Presentation on 6ix